{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-113463","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.331032+00:00","generated_at":"2026-06-22T16:49:24.880725+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rigel's fostamatinib misses primary endpoint in Phase 3 COVID-19 trial; p=0.0603","bullets":["FOCUS Phase 3 trial of fostamatinib in high-risk hospitalized COVID-19 patients did not meet primary endpoint for days on oxygen (p=0.0603).","Mean days on oxygen were 6.9 for fostamatinib vs 9.0 for placebo; mortality 4 vs 8 deaths (50% reduction, p=0.4521).","All prespecified secondary endpoints numerically favored fostamatinib, including ordinal scale change to Day 15 (-2.4 vs -1.9, p=0.0428).","Safety profile consistent with prior experience; no new safety issues; study supported by U.S. Department of Defense.","Company evaluating next steps in collaboration with partner, U.S. Department of Defense."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-113463","json":"https://secwatch.observer/filing/0001104659-22-113463.json","markdown":"https://secwatch.observer/filing/0001104659-22-113463.md","text":"https://secwatch.observer/filing/0001104659-22-113463.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465922113463/0001104659-22-113463-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465922113463/tm2229339d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T16:49:24.880725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}